The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis

PHASE2CompletedINTERVENTIONAL
Enrollment

213

Participants

Timeline

Start Date

June 21, 2017

Primary Completion Date

August 30, 2019

Study Completion Date

August 30, 2019

Conditions
Ulcerative Colitis
Interventions
DRUG

cobitolimod

Rectal administration

DRUG

Placebo

Solution manufactured to mimic cobitolimod

Trial Locations (64)

Unknown

1, Prague

2, Amiens

3, Caen

4, Clichy

5, Grenoble

6, Nice

7, Pierre-Bénite

8, Saint-Etienne

9, Toulouse

10, Vandœuvre-lès-Nancy

11, Augsburg

12, Berlin

13, Erlangen

14, Hamburg

15, Hanover

16, Heidelberg

17, Leipzig

18, Lüneburg

19, Mannheim

20, München

22, Békéscsaba

21, Budapest

23, Debrecen

24, Mosonmagyaróvár

25, Pécs

26, Częstochowa

27, Krakow

28, Ksawerów

33, Lodz

29, Lublin

30, Poznan

31, Sopot

32, Warsaw

33, Wroclaw

32, Włocławek

34, Cheboksary

36, Kazan'

37, Kirov

38, Moscow

39, Novosibirsk

40, Ryazan

41, Saint Petersburg

42, Stavropol

43, Tver'

44, Ufa

35, Yekaterinburg

45, Belgrade

46, Ferrol

47, Fuenlabrada

48, Madrid

49, Seville

50, Valencia

51, Uppsala

52, Chernivtsi

53, Dnipro

54, Ivano-Frankivsk

55, Kharkiv

56, Kiev

57, Lutsk

58, Lviv

59, Odesa

60, Sumy

62, Uzhhorod

61, Zaporizhzhya

Sponsors
All Listed Sponsors
lead

InDex Pharmaceuticals

INDUSTRY